Remove 2007 Remove Protein Production Remove Regulations
article thumbnail

The Active Ingredient Stands Alone

FDA Law Blog: Biosimilars

To set the stage for this case, we need to go back to March 2020 , when a new definition of “biological product” threw the world of protein products into a tizzy. That option would not have been available to InvaGen had the FDA instead determined that Somatuline Depot and InvaGen’s product were biological products.”

FDA 95
article thumbnail

A Look Back

Dark Matter Blog

Prior to that, I was CSO at RaNA Therapeutics (now Translate Bio), initially focused on targeting the function of long noncoding RNA in epigenetic regulation, and later transitioning to an mRNA therapeutics company. I had a first-hand role in raising money from Wall Street by being part of an IPO roadshow as Synta went public in 2007.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Codon Guide to Synthetic Biology

Codon

Link Gene Expression & Regulation →Genetic regulatory mechanisms in the synthesis of proteins , by Jacob F. & Gene Expression and Regulation. Link Biological Networks & Mathematics →Network motifs in the transcriptional regulation network of Escherichia coli , by Shen-Orr S.S. & Xie X.S.

DNA 91
article thumbnail

The Codon Guide to Synthetic Biology

Codon

Link Gene Expression & Regulation →Genetic regulatory mechanisms in the synthesis of proteins , by Jacob F. & Gene Expression and Regulation. Link Biological Networks & Mathematics →Network motifs in the transcriptional regulation network of Escherichia coli , by Shen-Orr S.S. & Xie X.S.

DNA 52